Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Yahoo Mail     Dropbox     Instagram     Slack     Google Drive     Print     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon


Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com


Buscar en contenido


lunes, 15 de mayo de 2017

Submasive PE-s

R.E.B.E.L. EM - Emergency Medicine Blog
R.E.B.E.L.EM - Episode 38 - May 15, 2017 - By Salim Rezaie
Post Peer Reviewed By: Anand Swaminathan
Ref.  Konstantinides SV et al. Impact of thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. J Am Coll Cardiol 2017; 69: 1536 – 44. PMID: 28335835
"Clinical Take Home Point: In the current trial, long-term mortality rates and long-term morbidity (residual dyspnea, functional limitations, and persistent RV dysfunction) were not affected by the use of systemic thrombolysis in unstratified patients with submassive PE. Thrombolysis in submassive PE should now only be considered in patients with signs of submassive PE and either at risk of throwing additional emboli to the lungs (proximal DVT or clot in transit on echo) or patients who appear to be at the brink of massive PE (pale, diaphoretic)."